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Primary dural lymphoma is a rare disease with more indolent clinical behavior compared to primary central nervous system
lymphoma. The majority of the reported cases were indolent marginal zone lymphoma subtype with more predilections to the
spine. Herein, we are presenting a case of intracranial, diﬀuse large B-cell lymphomaof the dura that was diagnosed and treated at
our institution. We are presenting the challenges in the treatment based on a review of the literature.
1.Introduction
Primary leptomeningeal lymphoma (PLML) is a known, ex-
ceedingly rare subtype of Primary Central Nervous System
Lymphoma (PCNSL), and it represents less than 0.1% of all
Non-Hodgkin’sLymphomas (NHL)[1].PLML isprimarily a
disease that originates from the meninges without any brain
orsystemic extension and/orinvolvement.Itusually presents
with nonspeciﬁc neurologic symptoms and signs such as
headache, meningeal signs, and cranial nerve involvement
with poor prognosis [2].
Primary Dural Lymphoma (PDL), a reported subentity
of PLML, is described as dura matter involvement with
no systemic disease. PDL is extremely rare disease, and it
represents less than 1% of all brain lymphomas [7–9].
The reported cases of PDL describe predominantly a
low-grade marginal zone lymphoma (MZL) with handful
of reported cases of other histologic subtype of lymphoma
[6, 10]. Herein, we reported a case of primary epidural
diﬀuse large B-cell lymphoma of a young lady diagnosed and
treated at Staten Island University Hospital.
2.CasePresentation
A 42-year-old Hispanic lady with no previous medical or
surgical history presented to our hospital in April 2008
complaining of right upper and lower extremity weakness
and numbness of 2-week duration associated with moderate
headaches and retro-orbital pain.
Her physical exam was not signiﬁcant except for 3/5
motoricity in RUE and RLE. The rest of neurologic exam
(sensation, cranial nerves, DTR, and cerebellar) was normal.
Complete blood count showed WBC 8600/µL, granulocytes
65.6%, lymphocytes 25.9%, monocytes 7.8%, basophiles
0.5% and eosinophils 0.2%, hemoglobin 12.9g/dL, hema-
tocrit 36.9%, MCV 89ﬂ, and platelets 347/µL. LDH level
was 239U/L (normal values 60–200U/L). A CT brain
with no contrast showed hyperdense extraaxial mass of
the left vertex abutting the superior sagittal sinus (2.5 ×
2.2 × 1.5cm) likely reﬂecting meningioma. An MRI with
and without gadolinium showed 2.4cm extraaxial mass
at the vertex compatible with meningioma which showed
intermediate signal on T1 and T2 sequences and enhanced
homogeneously, the sagittal sinus was compressed by the
mass, and the orbital and soft tissue of the skull base was
normal (Figure 1). She was seen by neurosurgery team.
A left parietal craniotomy with mass resection was done
3 days later. During the surgery, it was obvious that the
dura was thickened and perhaps involved by the tumor.
This was carefully taken oﬀ the brain and parenchyma.
At midline, the main portion of the tumor was identi-
ﬁed.2 ISRN Hematology
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Figure 1: MRI at diagnosis showingbroad-based attachment lesion to the meninges with indentation upon the adjacent brain parenchyma.
The pathology revealed malignant lymphoma, large cell
type, diﬀuse large B-cell immunophenotype with no brain
parenchyma identiﬁed indicating a dural diﬀuse large B-cell
lymphoma.ImmunochemicalstudiesshowedpositiveCD20,
CD45, CD3, CD5, CD15, BCL-6 and negative CD30, EMA,
BCL-2. In situ hybridization showed kappa-positive clonal
population for this large lymphoma.
A lumbar puncture post craniotomy was subsequently
performed. Gram stain, culture, cytology and ﬂow-cytom-
etry of the CSF were all normal. Spinal MRI was nega-
tive.
Staging work up done, including a normal bone marrow
aspirate and biopsy, normal routine cytogenetic and normal
CT scan of the chest, abdomen and pelvis as well as whole
body PET SCAN. Ophthalmologic exam was normal. At this
point, the patient diagnosis was stages IE diﬀuse large B-cell
Non-Hodgkin’s lymphoma involving the dural-based on
Ann Arbor staging system.
The patient was started adjuvant chemotherapy con-
sisting of high-dose methotrexate-based regimen every 2
weeks for four cycles (MTX 3gram/m2 on day 1, vin-
cristine 1.4mg/m2 on day 1 only cycles 1 and 3, procar-
bazine100mg/m2 day1throughday7oncycles1and3only)
in May 2008.
After four cycles, a repeated MRI brain with and with-
out contrast revealed patchy meningeal enhancement sub-
adjacent to the craniotomy site. A repeat PET SCAN
revealed hypermetabolic uptake in the previous left high
parietal craniotomy site, left posterior frontal sulcus and
left parietal sulci with max SUV value of 15,6. FDG uptake
was higher on this current study indicating residual disease.
Therefore four cycles of R-CHOP protocol every 3 weeks
were started in July 2008 (rituximab 375mg/m2 intravenous
on day 1, cyclophosphamide 750mg/m2 intravenous on day
1, adriamycin 50mg/m2 intravenous on day 1, vincristine
1.4mg/m2 intravenousonday1,and prednisone 100mgoral
day 1 through day 5).
A brain MRI was repeated afterward showing focal areas
of low T1, and high T2 high ﬂair intensity with no enhance-
ment was seen in left high medial frontal parietal paren-
chyma mostly representing postsurgical changes (Figure 2).
There was no evidence of recurrent or residual disease. No
radiation therapy was given at this time.
After the last cycle of R-CHOP (October, 2008), she has
been followed every 3 months that subsequently spaced out
to currently every 6 months with repeated blood work and
brain MRI that remained unchanged for 34 months. She
is been active with no neurological deﬁcit and no systemic
dissemination of the disease during all this period of time
until this report was concluded.
3.Discussion
PLML was ﬁrst described, in the early 1990s, histologically
as indolent type of B-cell lymphoma mainly extranodal
marginal zone predominantly seen in middle-aged woman
[2, 6, 10]. The main characteristic of PLML is the absence of
systemic as well as central nervous system involvement.
Since lymphoid tissue is absent in the dura, the patho-
genesis of PDL is still unclear, many hypotheses have been
formulated including the role of chronic inﬂammatory
process, chronic infection, autoimmune disease and the
meningoepithelial component [11–18].
Few case reports with other histological subtypes have
been described including, follicular, Hodgkin, and diﬀuse
large B-cell [3–6, 19].
Our case reported herein, is diagnosed as DLBCL of
the dura matter based on the histologic and immunohis-
tochemistry features of the malignant cells found only in
t h ed u r am a t t e ra sw e l la st h ea b s e n c eo fs y s t e m i ca n dC N S
parenchymal involvement.
Table 1 summarizes the reported cases of DLBCL of the
dura matter. Compared to previous reported dural DLBCL,
our case is the 1st report of intracranial location.ISRN Hematology 3
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Figure 2: MRI posttreatment showing resolution of the disease with postsurgical changes.
Table 1: Reported cases of primary dural DLBCL.
Reference Age
(years) Sex Location Therapy Survival status
(months) Residual disease
Epelbaum (1986) [3]
73
53
45
F
M
M
Spine
Spine
Spine
S+R
S+R+C
S+R+C
D (26)
D (20)
A (42)
−
+
−
Eeles (1991) [4]
71
61
54
M
F
M
Spine
Spine
Spine
S+C
S+R+C
S+R+C
D( 2 )
D (44)
A (43)
+
+
−
Lyons (1992) [5]
68
73
75
80
F
M
M
M
Spine
Spine
Spine
Spine
S+R
S+R
S+R
S+R
A (71)
D (24)
D (12)
D (10)
−
+
−
−
Miranda (1996) [6] 36
46
F
F
Spine
Spine
S+R
S+R+C
A (39)
A (13)
M: male; F: female; S: surgery; R: radiation therapy; C: chemotherapy;D: dead; A: alive.
Meningioma is the ﬁrst diﬀerential diagnosis with major
similarities in radiographic and clinical presentations. The
symptoms are usually dependant on the location of the
tumor, including headaches, seizures, focal sensory or motor
deﬁcits, and visual disturbances, as well as nausea, vomiting,
and ataxia [20, 21]. Cranial nerves dysfunction causing
bilateral visual and hearing loss due to progressive dural
involvement have been reported. Radicular pain and para-
paresis are the most presenting symptoms in the case of
spinal PDL [6].
Single or multiple dural-based extraaxial lesions that dif-
fusely enhance after gadolinium injection are the typical
radiologic feature on MRI. The presence of vasogenic
edema and parenchymal brain invasion with a fuzzy tumor-
brain interface is in favor of PDL more than meningiomas
[20]. The involvement of leptomeningeal space makes the
evaluation of CSF critical [20].
The clinical challenges that we face in managing our
patient can be summarized in 3 categories: (1) the type
of systemic adjuvant chemotherapy, (2) the role of radi-
ation therapy and (3) the role of prophylactic intrathecal
chemotherapy.
Due to the paucity of cases described in the literature,
there is no standard treatment available for PLML. Although
surgical treatment of dural MZL is considered the standard
modality of treatment, complete resection can be technically
diﬃcult. Complete surgical resection was achieved in our
patient, and this could be a contribution to the good overall
response.
T h eﬁ r s tc h a l l e n g ew a st h et y p eo fs y s t e m i ca d j u v a n t
chemotherapy and whether we should treat the patient as a
parenchymal CNS lymphoma with high-dose methotrexate
regimen or with R-CHOP regimen given the fact that this
is an extraparenchymal disease. The patient was given high4 ISRN Hematology
dose methotrexate regimen because of its good central
nervous system penetration. We thought that this character-
istic of methotrexate could be a helpful factor in avoiding
radiotherapy. In addition, the patient had an isolated dural
lesion with no other systemic disease which also made
methotrexate a more reasonable treatment; however, there
is no standard guideline in term of regimen the decision
should be made individually. The patient later received
R-CHOP because MRI ﬁnding suggested residual disease.
Currently, there is no gold standard imaging study which
can precisely diﬀerentiate between residual disease and post
surgical inﬂammatory changes, and when it is not clear,
waiting and repeat image is often the approach. However, we
did not feel that waiting would be an appropriate strategy
for our patient. On the other hand, pursuing another brain
biopsy was not feasible either. Therefore, we decided to give
hersecondround ofchemotherapy with R-CHOP,which can
further eradicate the residual disease.
Regarding the imaging modality to follow CNS lym-
phoma, we feel that enhanced MRI of the brain is more
reliable.Dataforuse ofPET scan inprimary CNSlymphoma
are lacking; PET can assess the metabolism within tumor
and normal tissue by using radio-labeled tracers. However,
false positivity isofconcern especially in the brain. The brain
directed PET may improve reading.
The other question is the role of radiation therapy in the
management of our patient. Cranial radiation therapy has
also been used for patients with primary CNS lymphoma
[22] after high dose systemic methotrexate chemotherapy.
Threeto4cycleR-CHOPfollowedbyinvolvedﬁeldradiation
therapyhasproducedexcellentoutcomeinpatientswithlim-
ited stage systemic DLBCL [23]. Should radiation be given
to our patient? There is no deﬁnitive answer; we felt that
beneﬁtandlongtermsideeﬀectfrombrainradiationtherapy
should be carefully weighed in this young otherwise healthy
patient.Givenshehasreceivedhighdosemethotrexatewhich
gives good blood-brain barrier penetration and given she
has isolated low volume disease; we thought that she could
avoidradiationupfront. Radiationcanbedeferredas salvage
treatment if she develops relapse disease.
The roleof intrathecal chemotherapyin themanagement
of PLML is unclear. We felt that our patient will not
beneﬁt much from intra-thecal methotrexate because of the
negative CSF analysis for malignant cell, the use of high
dose systemic methotrexate regimen which has good blood-
brain barrier penetration and the known ineﬃcacy of the
prophylactic intrathecal methotrexate in systemic DLBCL
[24].
4.Conclusion
Although it is a rare entity, primary dura matter lymphoma
exists. No standard of care is optimal due to its paucity;
therefore, any case is encouraged to be reported. From our
experience, the management should be a multidisciplinary
approach that involves the neurosurgery, radiation, and
medical oncology teams. Until more data are acquired, the
optimal treatment should be individualized.
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